ESMO: HER2-targeting antibody-drug improves progression-free survival for women with deadly form of advanced breast cancer

Researchers at UCLA’s Jonsson Comprehensive Cancer Center discovered that treating women with HER2-positive metastatic breast cancer with trastuzumab deruxtecan (T-DXd) significantly prolongs disease control and cancer growth compared to current standard of care, trastuzumab emtansine(T-DM1).

T-Dxd is a HER2-targeted monoclonal antibody that delivers high doses of chemotherapy directly to cancer cells that express HER2.

Compared to T-DM1, the medication improved progression-freesurvival by 72%.

At 12 months, 76 percent of patients treated with T-DXd had not progressed, meaning their disease remained under control. By 12 months,only 34% of T-DM1 patients had not progressed.

Read the full article here

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply